Carlsbad, CA, Sept. 06, 2023 (GLOBE NEWSWIRE) — Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced that it has entered into a licensing agreement with Giiant Pharma, Inc. (“Giiant”). The license provides the Company with…Read More
Palisade Bio Transforms GIFocused Pipeline Through Exclusive Worldwide Licensing Agreement with Giiant Pharma for Multiple Oral Drug Candidates Targeting Inflammatory Bowel Disease
